Champlain Investment Partners’s Maravai LifeSciences MRVI Stock Holding History

Champlain Investment Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,422,070	Closed	-$68.8M	–	133
2022 Q2	$68.8M	Sell	2,422,070 -1,160,460	-32%	-$36.8M	0.44%	93
2022 Q1	$126M	Buy	3,582,530 +28,405	+0.8%	+$952K	0.65%	70
2021 Q4	$149M	Buy	3,554,125 +270,304	+8%	+$10.9M	0.67%	64
2021 Q3	$161M	Sell	3,283,821 -171,804	-5%	-$8.38M	0.77%	53
2021 Q2	$144M	Buy	3,455,625 +1,746,410	+102%	+$67.7M	0.69%	61
2021 Q1	$60.9M	Buy	+1,709,215	New	+$56.6M	0.32%	108

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Champlain Investment Partners's MRVI Position: Q3 2022 in Review

Champlain Investment Partners sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 2,422,070 shares — an estimated $68.8M sold.

Champlain Investment Partners first reported a position in MRVI in Q1 2021 and held it in 6 quarters. The position peaked at $161M in Q3 2021. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

Champlain Investment Partners reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
Champlain Investment Partners sold 2,422,070 Maravai LifeSciences shares in Q3 2022, an estimated $68.8M.
Champlain Investment Partners first reported a position in Maravai LifeSciences in Q1 2021 and held it in 6 quarters.
Champlain Investment Partners's Maravai LifeSciences position peaked at $161M in Q3 2021.
202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on Champlain Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.